Sunday 8 November 2026 Export AIFF’s income statement to Excel — free account

Firefly Neuroscience, Inc.

Firefly Neuroscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 million, up 957.4% from fiscal 2024.

Revenue: +71.9%
EPS: +28.6%
Free cash flow: +25.4%

Quarter to June 2026, against a year earlier

0.91 0.00 0.00%

Follow AIFF

Alert me

Market cap: $14.3M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 4/9
Altman Z: −15.16
Beneish M: 1.09
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 30.80%

Capital & Financial Ratios $m

Size

Market Cap 14.28

Revenue ttm 1.80

Net income ttm (9.11)

Free cash flow ttm (7.20)

Net debt Q (9.23)

Valuation

P/E 0.00

Forward P/E —

Price / sales 10.41

Forward P/S Powerpack

Price / FCF 0.00

Price / book 1.28

Financial health

Current ratio Q 4.87

Debt / equity Q 0.00

Interest coverage Q (329.00)

Growth

Revenue growth Q +71.91%

Operating income growth Q −20.81%

EPS, this year —

EPS, next year A —

Revenue, next year A —

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 77.02%

10-year low 10-year high

P/B against its own 10 years 19.12%

10-year low 10-year high

EV/Sales against its own 10 years 72.26%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2	2	3	9
Receivables	0	0	0	0
Inventory	—	—	0	0
Other	—	—	—	—
	2	3	4	10

	2023	2024	2025	Q'26
Payables	1	2	1	1
ST’ Debt	—	—	—	—
Other	0	1	—	—
	3	5	3	2

Compound Annual Growth %

	10y	5y	3y
Sales	(15.58%)	(39.34%)	(53.03%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	13.37%	36.47%	26.98%

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.13)	(0.10)	—	—	—
’25	(1.74)	(0.14)	(0.20)	(0.16)	(1.97)
’24	(0.22)	(0.24)	(0.61)	(0.45)	(1.60)
’23	(2.10)	0.30	(0.18)	(0.29)	(0.81)
’22	(3.60)	(2.70)	(7.80)	(15.30)	(29.40)
’21	0.60	0.10	(0.23)	(3.30)	(2.70)
’20	(0.30)	(0.09)	0.60	0.90	1.03

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	1	—	—	—
’25	0	0	0	0	1
’24	0	0	0	0	0
’23	2	2	0	0	0
’22	3	4	2	2	11
’21	3	5	4	3	15
’20	2	5	4	3	14

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(3)	(2)	(1)	(2)	(8)
’24	(1)	(1)	(3)	(1)	(6)
’23	(2)	0	0	(1)	(2)
’22	(2)	(2)	(1)	(1)	(6)
’21	0	0	0	0	(1)
’20	0	0	1	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(3)	(2)	(2)	(2)	(8)
’24	(1)	(1)	(3)	(1)	(7)
’23	(2)	0	0	(1)	(3)
’22	(2)	(2)	(1)	(1)	(7)
’21	0	0	0	0	(1)
’20	0	0	1	0	0

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	7	11	9	10	14	15	11	0	0	1	2		(17.9%)	—	—	—	—
	Gross margin, %	27.09	22.70	23.99	13.77	15.89	24.05	25.97	100.00	100.00	56.48	44.58		+29.4 pt	Powerpack Firefly Neuroscience, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(1)	0	0	(1)	0	(2)	(5)	(3)	(10)	(20)	(9)		+48.9%
	EBT margin, %	(8.23)	2.32	(0.57)	(7.06)	2.97	(14.65)	(49.84)	(522.49)	(9,683.33)	(1,740.54)	(506.17)		(1,732.3) pt
	Net income	(1)	0	0	(1)	0	(1)	(18)	(3)	(10)	(20)	(9)		+48.9%
Per share, $
Per share, $	Revenue	18.02	28.50	23.93	27.21	37.16	35.87	18.70	0.15	0.02	0.09	0.09		(44.4%)
	Earnings	(1.50)	0.60	(0.14)	(1.80)	1.20	(2.70)	(29.40)	(0.81)	(1.60)	(1.97)	(0.59)		+3.1%
	Cash flow	(0.69)	2.24	(2.04)	(2.45)	1.13	(1.75)	(10.20)	(0.67)	(0.94)	(0.66)	(0.34)		(0.5%)
	Capex	(0.04)	0.00	(0.02)	(0.02)	(0.17)	(0.17)	(0.91)	(0.12)	(0.06)	(0.01)	(0.01)		(13.0%)
	Free cash flow	(0.72)	2.24	(2.06)	(2.48)	0.96	(1.92)	(11.11)	(0.79)	(1.00)	(0.67)	(0.35)		(0.9%)
	Book value	4.37	5.07	5.02	3.11	4.31	41.62	6.33	0.03	(0.06)	0.61	0.71		(19.6%)
	Shares, m	0	0	0	0	0	0	1	3	7	12	16		+47.6%
Valuation, ×
Valuation, ×	P/E	0.00	18.96	0.00	0.00	39.27	0.00	0.00	0.00	0.00	0.00	0.00		5.8
	P/S	0.23	0.44	0.18	0.15	1.17	4.14	0.83	3.81	160.64	9.59	10.41		18.1
	P/B	0.96	2.48	0.87	1.28	10.09	3.57	2.44	147.72	0.00	1.43	1.28		17.1
	EV/Sales	(0.05)	0.19	(0.04)	0.04	1.07	3.85	0.83	3.52	150.37	7.80	5.67		16.8
	EV/FCF	1.21	2.38	0.44	(0.48)	41.69	(71.94)	(1.40)	(5.49)	(2.36)	(1.05)	(1.39)		(3.7)
Cash, $m
Cash, $m	Operating cash flow	0	1	(1)	(1)	0	(1)	(6)	(2)	(6)	(8)	(7)		+46.9%
	Capex	0	0	0	0	0	0	(1)	0	0	0	0		+28.5%
	Free cash flow	0	1	(1)	(1)	0	(1)	(7)	(3)	(7)	(8)	(7)		+46.4%
Balance, $m
Balance, $m	Working capital	2	2	2	1	2	5	(1)	0	(2)	1	8		(3.1%)
	Net debt	(2)	(3)	(2)	(1)	(1)	(5)	0	(2)	(2)	(3)	(9)		+4.2%
	Shareholders’ equity	2	2	2	1	2	17	4	0	0	8	15		+18.7%
Returns, %
Returns, %	ROA	(14.07)	6.58	(1.51)	(26.57)	13.45	(8.34)	(113.28)	(49.01)	(288.87)	(325.39)	(59.52)		(311.3) pt
	ROIC	0.00	0.00	0.00	(166.87)	102.62	(12.93)	(98.92)	0.00	0.00	(113.19)	(105.08)		(113.2) pt
	ROE	(29.07)	13.98	(2.71)	(47.26)	29.79	(11.88)	(167.72)	(135.61)	7,864.66	(675.60)	(70.52)		(646.5) pt
People
People	Employees	25	23	24	24	37	55	61	43	13	17	—		(4.2%)
	Revenue/emp, $m	0.27	0.46	0.37	0.42	0.38	0.27	0.18	0.01	0.01	0.07	—		(14.3%)

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BMR Beamr Imaging Ltd.	$16.2M	—	—	—	—	−284.51% (below 0%: shrinking)	94.76%	0.00%	Compare
AIFF Firefly Neuroscience, Inc.	$14.3M	— (loss-making)	—	+71.91% (above 0%: growing)	n/m	+25.40% (above 0%: growing)	49.22%	(384.05%)
IPM Intelligent Protection Management Corp.	$14.3M	— (loss-making)	— (loss-making)	+12.93% (above 0%: growing)	n/m	+42.70% (above 0%: growing)	41.33%	(23.40%)	Compare
PDC Earlyworks Co., Ltd. Unsponsored ADR	$14.2M	—	—	—	—	−17.83% (below 0%: shrinking)	28.48%	0.00%	Compare
RPGL Republic Power Group Limited	$13.8M	—	—	—	—	−1,728.88% (below 0%: shrinking)	—	—	Compare
WQEY WISeQey Corp	$13.4M	— (loss-making)	—	+55.93% (above 0%: growing)	n/m	−92.17% (below 0%: shrinking)	52.94%	0.00%	Compare
IFBD Infobird Co., Ltd.	$13.3M	— (loss-making)	— (loss-making)	−64.75% (below 0%: shrinking)	+85.14% (above 0%: growing)	+80.81% (above 0%: growing)	36.20%	0.00%	Compare
AHI Advanced Human Imaging Limited Sponsored ADR	$13.2M	— (loss-making)	— (loss-making)	+307.96% (above 0%: growing)	+49.62% (above 0%: growing)	−21.40% (below 0%: shrinking)	0.00%	0.00%	Compare
SMSI Smith Micro Software, Inc.	$12.8M	— (loss-making)	— (loss-making)	−1.79% (below 0%: shrinking)	n/m	+61.05% (above 0%: growing)	81.32%	(54.57%)	Compare
Median of peers	$13.6M	—	—	+12.93%	—	−19.61%	41.33%	0.00%

All 230 Software Application stocks →

Pay and ownership Proxy statement filed 9 July 2026

Ownership

Directors and executive officers, together 6.90%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Firefly Neuroscience, Inc. (AIFF) Latest News

27 Oct

Impact 4 · 7:45 AM · GlobeNewswire

Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform

25 Sep

Impact 4 · 7:45 AM · GlobeNewswire

Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

17 Sep

Impact 4 · 7:50 AM

Firefly Neuroscience’s Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial’s AI-Native Operating System for Brain Medicine

5 Aug

Impact 4 · 7:45 AM

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

28 Jul

Impact 4 · 7:50 AM

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Impact 4 · 8:00 AM · Business Wire

Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease at AAIC 2025

2 Jun

Impact 4 · 7:40 AM · GlobeNewswire

Firefly’s AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD

13 Apr

Impact 5 · 7:45 AM · GlobeNewswire

With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World’s First Known 200,000+ Standardized EEG/ERP Depository

26 Mar

Impact 5 · 7:45 AM · GlobeNewswire

Firefly Confirms Public-Private Partnership with the Department of War

13 Mar

Impact 4 · 7:55 AM · GlobeNewswire

Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD

4 Mar

Impact 4 · 7:45 AM · GlobeNewswire

Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration

12 Nov

Impact 3 · 7:45 AM · GlobeNewswire

Firefly Neuroscience Reports Third Quarter 2025 Financial Results

5 Sep

Impact 4 · 7:55 AM · GlobeNewswire

Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America

26 Aug

Impact 4 · 7:45 AM · GlobeNewswire

Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform

Impact 3 · 10:30 AM · Associated Press Finance

BC-Most Active Stocks

14 Jul

Impact 4 · 7:45 AM · GlobeNewswire

Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research

23 Jun

Impact 4 · 8:05 AM

Firefly Neuroscience to be Added to the Russell Microcap® Index

20 Jun

Impact 4 · 7:45 AM · GlobeNewswire

Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients

5 May

Impact 4 · 9:00 PM · GlobeNewswire

Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

Impact 4 · 7:45 AM · GlobeNewswire

Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

6 Mar

Impact 4 · 7:30 AM

Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

21 Feb

Impact 4 · 8:00 AM · GlobeNewswire

Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million

11 Feb

Impact 4 · 7:45 AM · GlobeNewswire

Firefly Neuroscience Accepted into NVIDIA Connect Program

7 Feb

Impact 4 · 7:30 AM · GlobeNewswire

Firefly Neuroscience Congratulates Scientific Advisor, Dr. Christopher Wilson, Recipient of Prestigious UW Faculty of Engineering Award for Work on Superconducting Quantum Electronics

24 Jan

Impact 4 · 9:00 AM

Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care

14 Jan

Impact 4 · 7:45 AM · GlobeNewswire

Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform

31 Dec

Impact 4 · 9:00 AM

Firefly Neuroscience Closes on Financing of up to $12.4 Million

4 Dec

Impact 3 · 9:00 AM

Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman

16 Nov

Impact 4 · 8:40 AM earnings

Firefly Neuroscience Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$0.18 loss in 3Q 2023)

14 Nov

Impact 3 · 5:30 PM

Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Firefly Neuroscience, Inc. vs peers in Software Application (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 9 July 2026

Ownership

Firefly Neuroscience, Inc. (AIFF) Latest News

27 Oct

25 Sep

17 Sep

5 Aug

28 Jul

2 Jun

13 Apr

26 Mar

13 Mar

4 Mar

12 Nov

5 Sep

26 Aug

14 Jul

23 Jun

20 Jun

5 May

6 Mar

21 Feb

11 Feb

7 Feb

24 Jan

14 Jan

31 Dec

4 Dec

16 Nov

14 Nov

Stockrow Weekly